摘要
目的 探讨体外培养的原代软骨细胞及加入白细胞介素 (IL) 1β诱导软骨细胞中金属蛋白酶 /金属蛋白酶抑制剂水平变化及四环素、强力霉素及中药骨碎补对其影响。方法 采用体外培养的兔软骨原代细胞为模型 ,分别加入含有 10 %四环素、强力霉素及骨碎补含药血清 ,实验组加入10ng/mlIL 1β ,诱导软骨细胞变性 ,均培养 4 8h分离上清液 ,采用酶联免疫方法测定各组培养液中基质金属蛋白酶 3(MMP 3)及金属蛋白酶组织抑制剂 1(TIMP 1)含量。结果 经 10ng/mlIL 1β诱导后 ,软骨细胞MMP 3/TIMP 1水平显著性升高 (P <0 0 1) ;对于加入IL 1β诱导的软骨细胞 ,与空白血清对照组比较 ,含骨碎补药物血清和含强力霉素药物血清均降低软骨细胞MMP 3/TIMP 1水平 ,且强力霉素含药血清组与空白对照组比较差异具有显著性 (P <0 0 1) ,而含四环素药物血清则升高软骨细胞MMP 3/TIMP 1水平 ,但与空白对照组比较差异无显著性 (P >0 0 5 ) ;对于不加IL 1β诱导的软骨细胞来说 ,3种含药血清均可升高软骨细胞MMP 3/TIMP 1水平 ,且含骨碎补药物血清和含四环素药物血清与空白对照组比较差异均有显著性 (P <0 0 1)。结论 IL 1β可上调体外培养的原代软骨细胞MMP 3/TIMP 1水平 ,强力霉素和骨碎补可以下调经IL
Objective To investigate the expression and role of metalloproteinases (MMPs) and tissue type inhibitors of metalloproteinases (TIMPs) in interleukin -1 (IL-1) beta treated rabbit chondrocytes in vitro,and to assess the effects of selected drugs.Methods The drug serum of containing 10% tetracycline or deoxycycline and rhizoma drynariae was added to culture medium of rabbit articular chondrocyte treated with 10 ng/ml IL-1 beta,and levels of MMP-3 and TIMP-1 in each group were determined by ELISA.Results The MMP-3/TIMP-1 levels of chondrocytes were markelly elevated in all groups after treatment by 10 ng/ml IL-1 beta (P<0.01).The analysis of the MMP-3/TIMP-1 of chondrocytes added to drug serums containing deoxycycline and rhizoma drynariae showed that their levels were lower than those of control group.There was significant difference between groups of drug serums containing deoxycycline and normal control group.The level of MMP-3/TIMP-1 was insignificantly up-regulated by tetracycline.On the other hand,The levels of MMP-3 /TIMP-1 in chondrocytes not treated with 10 ng/ml IL-1 beta,compared with normal control groups,were found a significant increase (P<0.01).Conclusion The levels of MMP-3/TIMP-1 are up-regulated by IL-1 beta in explant culture of rabbit chondrocytes.While deoxycycline and rhizoma drynariae down-regulate the MMP-3/TIMP-1 level in explant culture of rabbit chondrocytes treated with 10 ng/ml IL-1 beta.
出处
《中华风湿病学杂志》
CAS
CSCD
2003年第12期718-721,共4页
Chinese Journal of Rheumatology
基金
卫生部科研基金资助项目 ( 96 2 2 5 4)
